Chimerix To Present At Two Upcoming Healthcare Conferences In November

RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced presentations at two upcoming investor conferences in New York. Both presentations will include an update on the Company's clinical pipeline, including its lead development compound, CMX001.

• Kenneth I. Moch, President & CEO, will present at the Lazard Capital Market 9th Annual Healthcare Conference on Wednesday, November 14 at 2:30 pm ET at The Pierre Hotel.  This presentation will not be webcast.
• Mr. Moch will present at the 24th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28 at 10:30 am at The New York Palace.  A live audio webcast of this presentation can be accessed at http://www.media-server.com/m/p/iz69925g or in the News & Resources section of the Company website at www.chimerix.com and will be archived for 30 days.

About Chimerix
Chimerix is developing novel oral antiviral therapeutics with the potential to improve outcomes for patients in multiple therapeutic areas, including transplant, oncology, acute care and global health.  The Company's proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates that have demonstrated the potential for enhanced activity and safety compared with currently approved drugs. 

Chimerix's lead clinical-stage drug candidate, CMX001, is a novel, broad-spectrum, oral antiviral that inhibits double-stranded DNA (dsDNA) viruses, including cytomegalovirus (CMV), adenovirus (AdV), BK virus and herpes simplex virus.  CMX001 has completed Phase 2 clinical development for the prophylaxis of CMV in hematopoietic stem cell transplant (HSCT) recipients and is in Phase 2 development for the preemption and treatment of AdV infection.  To date, more than 800 patients have been dosed with CMX001 in controlled clinical trials and open-label treatment protocols.  Chimerix has completed an End of Phase 2 meeting with the U.S. Food and Drug Administration and is preparing to initiate Phase 3 clinical development of CMX001 for the prophylaxis of CMV in HSCT recipients in 2013.   

In addition to its commercial use, CMX001 is being developed under a contract from the Biomedical Advanced Research and Development Authority (BARDA) as a medical countermeasure to protect against a bioterror threat in the event of a smallpox release. 

In July 2012, Chimerix granted an exclusive worldwide license to Merck for the development and commercialization of its second clinical-stage drug candidate, CMX157, for the treatment of HIV infection, further validating the Company's propriety lipid technology. 

For more information, please visit www.chimerix.com.

SOURCE Chimerix, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED